tetano
Editor, Senior Moderator
Commun Biol
. 2025 Nov 24;8(1):1643.
doi: 10.1038/s42003-025-09034-3. Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters
Núria Pedreño-López[SUP] 1 [/SUP], Ferran Tarrés-Freixas[SUP] 2 3 4 [/SUP], Carla Usai[SUP] 2 3 [/SUP], Dalia Raïch-Regué[SUP] 1 [/SUP], Susana Benet[SUP] 5 6 [/SUP], Erola Ainsua-Enrich[SUP] 1 [/SUP], Julieta Carabelli[SUP] 1 [/SUP], Edwards Pradenas[SUP] 1 [/SUP], Carlos Ávila-Nieto[SUP] 1 [/SUP], Núria Roca[SUP] 2 3 [/SUP], Guillermo Cantero[SUP] 2 3 [/SUP], Mònica Pérez[SUP] 2 3 [/SUP], Maria Luisa Rodríguez de la Concepción[SUP] 1 [/SUP], Marina Matilla[SUP] 1 [/SUP], Boris Revollo[SUP] 5 6 [/SUP], Agnes Hernández[SUP] 6 [/SUP], Jorge Abad-Capa[SUP] 6 [/SUP], Beatriz Mothe[SUP] 1 5 7 [/SUP], Jose Moltó[SUP] 5 6 7 8 [/SUP], Lourdes Mateu[SUP] 5 6 8 9 [/SUP], Marta Massanella[SUP] 1 7 [/SUP], Nuria Izquierdo-Useros[SUP] 1 7 8 [/SUP], Julià Blanco[SUP] 1 4 7 8 [/SUP], Bonaventura Clotet[SUP] 1 5 7 8 [/SUP], Joaquim Segalés[SUP] 2 10 [/SUP], Júlia Vergara-Alert[SUP] 11 12 [/SUP], Jorge Carrillo[SUP] 13 14 15 [/SUP]
Affiliations
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes.
. 2025 Nov 24;8(1):1643.
doi: 10.1038/s42003-025-09034-3. Anti-SARS-CoV-2 antibodies from severe COVID-19 individuals or S2 immunizations do not worsen disease in hamsters
Núria Pedreño-López[SUP] 1 [/SUP], Ferran Tarrés-Freixas[SUP] 2 3 4 [/SUP], Carla Usai[SUP] 2 3 [/SUP], Dalia Raïch-Regué[SUP] 1 [/SUP], Susana Benet[SUP] 5 6 [/SUP], Erola Ainsua-Enrich[SUP] 1 [/SUP], Julieta Carabelli[SUP] 1 [/SUP], Edwards Pradenas[SUP] 1 [/SUP], Carlos Ávila-Nieto[SUP] 1 [/SUP], Núria Roca[SUP] 2 3 [/SUP], Guillermo Cantero[SUP] 2 3 [/SUP], Mònica Pérez[SUP] 2 3 [/SUP], Maria Luisa Rodríguez de la Concepción[SUP] 1 [/SUP], Marina Matilla[SUP] 1 [/SUP], Boris Revollo[SUP] 5 6 [/SUP], Agnes Hernández[SUP] 6 [/SUP], Jorge Abad-Capa[SUP] 6 [/SUP], Beatriz Mothe[SUP] 1 5 7 [/SUP], Jose Moltó[SUP] 5 6 7 8 [/SUP], Lourdes Mateu[SUP] 5 6 8 9 [/SUP], Marta Massanella[SUP] 1 7 [/SUP], Nuria Izquierdo-Useros[SUP] 1 7 8 [/SUP], Julià Blanco[SUP] 1 4 7 8 [/SUP], Bonaventura Clotet[SUP] 1 5 7 8 [/SUP], Joaquim Segalés[SUP] 2 10 [/SUP], Júlia Vergara-Alert[SUP] 11 12 [/SUP], Jorge Carrillo[SUP] 13 14 15 [/SUP]
Affiliations
- PMID: 41286076
- PMCID: PMC12644488
- DOI: 10.1038/s42003-025-09034-3
Severe COVID-19 associates with humoral immune response dysregulation. While antibodies confer protection against SARS-CoV-2, evidence also support their putative contribution to disease severity. Our study demonstrates that higher levels of S2-IgG, and S2-, RBD-, and Nucleocapsid-IgA differentiate severe and non-severe cases. However, no major antibody functional differences are found between both COVID-19 manifestations. Enhanced Fc-dependent functions in severe cases are primarily driven by increased antibody titers. No differences in antibody avidity are found between severe and non-severe cases, but a gradation in binding strength across specificities suggests that early anti-RBD, -S2, and -Nucleocapsid antibodies may originate from different pathways. In golden Syrian hamsters, S2 immunization or transfer of RBD-depleted antibodies isolated from severe and non-severe cases promote a faster clinical recovery after SARS-CoV-2 challenge, despite a transient initial weight loss. These findings indicate that antibodies are not major determinants of COVID-19 severity and suggest additional factors influencing disease outcomes.